Investigation of an alternative to direct anticoagulants in COVID-19 patients

Currently, the use of anticoagulants is a mandatory component of the complex therapy of COVID-19. Regarding the choice of drugs and their dosages, there is no consensus yet. Increasing doses reduces the risk of thrombosis, but at the same time increases the risk of bleeding, which is a common event in severe COVID-19. This makes it relevant to study alternative options for thromboprophylaxis. The aim of this study was to compare the efficacy and safety of oral sulodexide and dabigatran etexilate in patients with COVID-19. Sulodexide demonstrated the same clinical efficacy as dabigatran in the treatment of patients with a degree of lung damage not higher than CT-2, while the relief of the initially existing coagulopathy occurred significantly faster, and there was no excessive increase in thrombin time, characteristic of dabigatran.